Keywords: Alnylam Pharma, Tekmira Pharma, RNAi therapeutics, Litigation, Settlement

Alnylam and Tekmira restructure relationship and settle all litigation in $65 million deal

Article | 14 November 2012

USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) says it has restructured its relationship with Canadian developer of RNA interference (RNAi) therapeutics Tekmira ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Alnylam Pharmaceuticals

Tekmira Pharmaceuticals

Go to company listing